Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;51(6):1035-40.
doi: 10.1007/s00125-008-0992-1. Epub 2008 Apr 4.

Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand

G Mabilleau  1 , N L Petrova, M E Edmonds, A Sabokbar
Affiliations

Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand

G Mabilleau et al. Diabetologia. 2008 Jun.

Abstract

Aims/hypothesis: Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG).

Methods: Peripheral blood monocytes isolated from nine diabetic Charcot patients, eight diabetic control and eight healthy control participants were cultured in the presence of macrophage-colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and RANKL with excess concentrations of OPG. Osteoclast formation was assessed by expression of tartrate-resistant acid phosphatase on glass coverslips and resorption on dentine slices.

Results: In cultures with M-CSF, there was a significant increase in osteoclast formation in Charcot patients compared with healthy and diabetic control participants (p=0.008). A significant increase in bone resorption was also seen in the former, compared with healthy and diabetic control participants (p<0.0001). The addition of RANKL to the cultures with M-CSF led to marked increase in osteoclastic resorption in Charcot (from 0.264+/-0.06% to 41.6+/-8.1%, p<0.0001) and diabetic control (0.000+/-0.00% to 14.2+/-16.5%, p<0.0001) patients, and also in healthy control participants (0.004+/-0.01% to 10.5+/-1.9%, p<0.0001). Although the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of resorption in Charcot patients (41.6+/-8.1% to 5.9+/-2.4%, p=0.001), this suppression was not as complete as in diabetic control patients (14.2+/-16.5% to 0.45+/-0.31%, p=0.001) and in healthy control participants (from 10.5+/-1.9% to 0.00+/-0.00%, p<0.0001).

Conclusions/interpretation: These results indicate that RANKL-mediated osteoclastic resorption occurs in acute Charcot's osteoarthropathy. However, the incomplete inhibition of RANKL after addition of OPG also suggests the existence of a RANKL-independent pathway.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Multinucleated TRAcP-positive cells were formed on glass coverslips (a, c, e) capable of lacunar resorption (b, d, f) after 14 and 21 days incubation, respectively, in the presence of 25 ng/ml human M-CSF and 100 ng/ml sRANKL. Newly formed osteoclasts were numerous and highly active in Charcot’s patients (a, b) compared with diabetic (c, d) and healthy control (e, f) participants. Scale bars, 10 μm
Fig. 2
Fig. 2
a Quantitative comparison between the number (n) of TRAcP-positive cells formed in cultures with M-CSF alone (white bars) or with M-CSF and sRANKL (black bars) in patients with Charcot’s osteoarthropathy and diabetic and healthy control participants. b Quantitative comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann–Whitney U test, with significance as follows: a Charcot’s p = 0.059, diabetic control p = 0.003, healthy control p = 0.002; b Charcot’s p < 0.0001, diabetic control p < 0.0001, healthy control p < 0.0001
Fig. 3
Fig. 3
a Comparison between the number (n) of TRAcP-positive cells formed in cultures with M-CSF and sRANKL (black bars) or with M-CSF, sRANKL and excess concentrations of OPG (250 ng/ml) (grey bars) in patients with Charcot’s osteoarthropathy and diabetic and healthy control participants. b Comparison between the percentage area resorption in the same cultures and patient groups. Statistical differences between the groups were determined using the Mann–Whitney U test, with significance as follows: a Charcot’s p = 0.189, diabetic control p = 0.005, healthy control p = 0.003; b Charcot's p = 0.001, diabetic control p = 0.001, healthy control p < 0.0001
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/(SICI)1096-9136(199707)14:7<527::AID-DIA404>3.0.CO;2-Q', 'is_inner': False, 'url': 'https://doi.org/10.1002/(sici)1096-9136(199707)14:7<527::aid-dia404>3.0.co;2-q'}, {'type': 'PubMed', 'value': '9223389', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9223389/'}]}
    2. Gough A, Abraha H, Li F et al (1997) Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 14:527–531 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1126/science.289.5484.1504', 'is_inner': False, 'url': 'https://doi.org/10.1126/science.289.5484.1504'}, {'type': 'PubMed', 'value': '10968780', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10968780/'}]}
    2. Teitelbaum SL (2000) Bone resoption by osteoclasts. Science 289:1504–1508 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1073/pnas.95.7.3597', 'is_inner': False, 'url': 'https://doi.org/10.1073/pnas.95.7.3597'}, {'type': 'PMC', 'value': 'PMC19881', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC19881/'}, {'type': 'PubMed', 'value': '9520411', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9520411/'}]}
    2. Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/jama.292.4.490', 'is_inner': False, 'url': 'https://doi.org/10.1001/jama.292.4.490'}, {'type': 'PubMed', 'value': '15280347', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15280347/'}]}
    2. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/ RANKL /RANK system for bone and vascular diseases. JAMA 292:490–495 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00125-004-1477-5', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00125-004-1477-5'}, {'type': 'PubMed', 'value': '15322748', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15322748/'}]}
    2. Jeffcoate W (2004) Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link? Diabetelogia 47:1488–1492 - PubMed

Publication types

Substances